John W. Smallridge

2 papers in the library · 1 citation · publishing 2026

Papers

Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 1, 2026 Cheng-Teng Ip, Sebastian Olbrich, Mateo de Bardeci et al. 1 citation

In a double-blind, randomized, crossover, placebo-controlled trial with 25 healthy adults, psilocybin (10–20 mg oral) decreased EEG power in slow frequency bands (theta and alpha) and increased power in fast frequency bands (beta, gamma1, gamma2) compared to placebo. Connectivity within the default-mode network and localized parietal network increased under psilocybin. Changes in EEG power and connectivity correlated positively with subjective experiences measured by the Altered States of Consciousness Questionnaire. Baseline EEG features predicted subjective alterations, suggesting that specific brain activity patterns could serve as biomarkers for tailoring psilocybin therapy.

DOI: 10.1016/j.pnpbp.2026.111626 Electroencephalography Dynamics music Neurophysiology Artificial neural network +4

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [¹⁸F]FDG-PET study

Repository for Publications and Research Data (ETH Zurich) January 1, 2026 Klemens Egger, Robert Bozsak, Helena D. Aicher et al.

A psychedelic dose of DMT combined with harmine, mimicking ayahuasca, globally increased cerebral glucose metabolism by 12.5% in 14 healthy males, as measured by PET scans during peak drug effects. This increase was widespread across the cortex, particularly in higher-order brain networks, and positively correlated with harmine plasma levels but not with DMT levels or subjective intensity. The finding recapitulates a classic effect seen with psilocybin, suggesting a potential metabolic signature of the psychedelic state.

DOI: 10.3929/ethz-c-000801722 Harmine Placebo Neuroimaging Metabolite +12